SOURCE: AGI Therapeutics plc

March 05, 2008 09:01 ET

AGI Therapeutics Plc announces Cowen Healthcare Conference

Dublin, Ireland--(Marketwire - March 5, 2008) -


 AGI Therapeutics to present at Cowen and Company 28th Annual Health Care
                              Conference in Boston

                     -- 4.45 p.m., Monday 17 March, 2008 --


Dublin, Ireland, 5 March 2008 - AGI Therapeutics plc ("AGI" or the "Company")
(AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal
drug products, today announces that the Company's President of U.S. Operations,
Dr. David Young, and Chief Financial Officer, David Kelly, will make a
presentation at the Cowen and Company 28th Annual Health Care Conference in
Boston. The conference will be held at the Boston Marriott, Copley Place.

AGI will present on Monday 17 March at 4.45 p.m. EST (9.45 p.m. GMT).  A copy of
the presentation will be available after the event on the AGI website at
www.agitherapeutics.com under the "Investors: Publications" tab.


Contact Information:

AGI Therapeutics plc.                         Tel: +353 1 449 3254
David Kelly, Chief Financial Officer

Financial Dynamics - UK                        Tel: +44 (0) 20 7269 7182
Deborah Scott/Lara Mott

Financial Dynamics - Ireland                   Tel: +353 1 663 3607
Aisling Garvey


Notes to Editors:

About AGI Therapeutics plc

AGI is a speciality pharmaceutical company which is focused on the development
and commercialisation of differentiated drug products for gastrointestinal (GI)
diseases and disorders. AGI's common shares are listed on the Alternative
Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise
Exchange of the Irish Stock Market (IEX) as AGI.

The Company has a portfolio of product candidates derived from its Known
Molecular Entity (KME) approach to drug re-profiling and development. The
Company's lead product candidate, Rezular, is an orally administered
triple-action intestinal regulator, a first-in-class mechanism for the treatment
of Diarrhoea predominant Irritable Bowel Syndrome, (IBS-D).  Rezular is
currently in Phase III clinical trials.

KME is a re-profiling methodology used by the Company to identify existing
therapeutic drugs which typically have been marketed for a number of years, have
established safety profiles and can be developed for new clinical indications or
with improved profiles in their existing clinical indications.  In this way, the
Company seeks to reduce the risk, time and cost of new product development as
compared to the development of new chemical entities.

AGI is developing a range of product candidates to treat a variety of prevalent
GI diseases and disorders, including irritable bowel syndrome (IBS), dyspepsia,
gastroparesis, ulcerative colitis, gastro-esophageal reflux disease (GERD) and
diarrhoea-related conditions such as chemotherapy-induced diarrhoea (CID).  The
Company is targeting areas of the GI therapeutic drug products market for its
product candidates where there are currently unmet medical needs or where the
effectiveness of existing drug therapies can be further improved.

The Company has five active clinical stage product candidates which are either
isomers or new drug delivery formulations of existing approved drugs, and which
have established safety and tolerability profiles in their currently approved
clinical indications.

For further information please see www.agitherapeutics.com

Statements contained within this press release may contain forward-looking
comments which involve risks and uncertainties that may cause actual results to
vary from those contained in the forward-looking statements. In some cases, you
can identify such forward-looking statements by terminology such as 'may', '
will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', '
estimates', 'predicts', 'potential', or 'continue'. Predictions and
forward-looking references in this press release are subject to the satisfactory
progress of research which is, by nature, unpredictable. Forward projections
reflect management's best estimates based on information available at the time
of issue.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END